Royalty PharmaRPRX
RPRX
About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees: 99
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
160% more call options, than puts
Call options by funds: $89M | Put options by funds: $34.2M
68% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 50
21% more capital invested
Capital invested by funds: $8.18B [Q4 2024] → $9.86B (+$1.68B) [Q1 2025]
7% more funds holding
Funds holding: 411 [Q4 2024] → 440 (+29) [Q1 2025]
7% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 146
0.92% more ownership
Funds ownership: 72.13% [Q4 2024] → 73.04% (+0.92%) [Q1 2025]
22% less funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 7 (-2) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$54
51%
upside
Avg. target
$54
51%
upside
High target
$54
51%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Terence Flynn | 51%upside $54 | Overweight Maintained | 10 Jul 2025 |
Financial journalist opinion
Based on 3 articles about RPRX published over the past 30 days
Neutral
Seeking Alpha
1 week ago
Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline
Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. The Revolution Medicines royalty deal provides near-term upside and de-risks pipeline assets, with pivotal data expected in 2026. We forecast 2025 EPS of $4.53 and raise our target price to $45.3, reflecting strong earnings and capital deployment.
Positive
Reuters
2 weeks ago
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Royalty Pharma said on Tuesday will pay up to $2 billion to Revolution Medicines to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib.
Neutral
GlobeNewsWire
2 weeks ago
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million. These funds will support Revolution Medicines' plans for global development and commercialization of daraxonrasib and its pipeline programs for patients with RAS-addicted cancers.
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma Completes the Acquisition of Its External Manager
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction.
Neutral
GlobeNewsWire
2 months ago
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Neutral
GlobeNewsWire
2 months ago
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for the company.
Positive
Seeking Alpha
2 months ago
Royalty Pharma: Again, Guidance Raised, Buy Confirmed
Royalty Pharma reported 12% growth in Q1 royalty receipts, driven by Vertex, GSK, and Roche, with adjusted EBITDA reaching $738 million. The company raised its 2025 Portfolio Receipts guidance to $2.97-$3.12 billion, suggesting potential growth opportunities not yet reflected in the current valuation. RPRX repurchased 23 million shares for $723 million and has a $2.3 billion buyback remaining, with a 2.6% dividend yield.
Neutral
Seeking Alpha
2 months ago
Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants George Grofik - Senior Vice President and Head, Investor Relations and Communications Pablo Legorreta - Founder and CEO Marshall Urist - Executive Vice President and Head, Research and Investment Terry Coyne - Executive Vice President and CFO Chris Hite - Executive Vice President and Vice Chairman Conference Call Participants Hardik Parikh - JPMorgan Mike Nedelcovych - TD Cowen Terence Flynn - Morgan Stanley Geoff Meacham - Citi Jason Gerberry - Bank of America Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call.
Neutral
Zacks Investment Research
2 months ago
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charts implemented using Lightweight Charts™